Skip to content

New retinal gene therapy company, NightstaRx Ltd, is spun out of University of Oxford with £12M venture funding

Syncona LLP, an independent subsidiary of the Wellcome Trust, the University of Oxford, and its technology transfer arm, Isis Innovations, have announced a £12 million investment in a new spin-out focused on the development and commercialisation of therapies for retinal dystrophies. The new company, named NightstaRx Ltd, will initially develop a gene therapy treatment for choroideremia, a gene therapeutic approach developed by Professor Robert MacLaren at Oxford’s Nuffield Laboratory of Ophthalmology.